Literature DB >> 8191235

Substantial decline of notified hepatitis B in major parts of Europe after 1985.

S Iwarson1, W Jilg, T Stroffolini.   

Abstract

A decline in the incidence of notified hepatitis B cases has been observed in major parts of Europe since the mid-1980s. Sweden may be taken as an example of a low prevalence area in the north where notifications of acute hepatitis B declined from 6 cases/100,000 inhabitants in 1985 to only 3/100,000 annually in 1988-91. Choosing W. Germany as an example from central Europe, the notification rate of acute hepatitis B declined from 11 cases/100,000 inhabitants in 1984 to 6-8/100,000 in 1988-91. In Italy, a dramatic decline in hepatitis B infections has occurred since 1985, according to the national hepatitis surveillance system (SEIEVA), from 12 cases/100,000 inhabitants in 1985 to 5/100,000 in 1988-91. A similar trend has also been observed in the USA which seems to be unrelated to vaccination, since only limited vaccination programs have been initiated in high-risk groups. Also in Europe, changed sexual and needle-usage practices in risk groups such as drug addicts and male homosexuals have probably contributed to the observed decline. In southern Europe, rapidly improving socio-economic conditions and improved medical precautions against hepatitis B have probably also been important factors.

Entities:  

Mesh:

Year:  1994        PMID: 8191235     DOI: 10.3109/00365549409008585

Source DB:  PubMed          Journal:  Scand J Infect Dis        ISSN: 0036-5548


  6 in total

1.  Prevalence and risk factors for hepatitis B virus infections among visitors to an STD clinic.

Authors:  Y T van Duynhoven; M J van de Laar; W A Schop; P H Rothbarth; W I van der Meijden; A M van Loon; M J Sprenger
Journal:  Genitourin Med       Date:  1997-12

2.  Decline of hepatitis B infection in Greece.

Authors:  M Stamouli; V Gizaris; G Totos; G Papaevangelou
Journal:  Eur J Epidemiol       Date:  1999-05       Impact factor: 8.082

3.  The economic burden of hepatitis B in Germany.

Authors:  S Harbarth; T Szucs; K Berger; W Jilg
Journal:  Eur J Epidemiol       Date:  2000-02       Impact factor: 8.082

4.  Costs and cost-effectiveness of a universal, school-based hepatitis B vaccination program.

Authors:  M Krahn; R Guasparini; M Sherman; A S Detsky
Journal:  Am J Public Health       Date:  1998-11       Impact factor: 9.308

5.  An epidemic of hepatitis B virus infection among intravenous drug users in Iceland.

Authors:  A Löve; B Stanzeit
Journal:  Eur J Epidemiol       Date:  1995-08       Impact factor: 8.082

6.  Six years of sentinel surveillance of hepatitis B in general practice in France.

Authors:  V Massari; P Maison; J C Desenclos; A Flahault
Journal:  Eur J Epidemiol       Date:  1998-12       Impact factor: 8.082

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.